Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Common Equity: 2017-2023

Historic Common Equity for Solid Biosciences (SLDB) over the last 7 years, with Dec 2023 value amounting to $126.5 million.

  • Solid Biosciences' Common Equity rose 15.70% to $167.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $167.0 million, marking a year-over-year increase of 15.70%. This contributed to the annual value of $126.5 million for FY2023, which is 40.25% down from last year.
  • Latest data reveals that Solid Biosciences reported Common Equity of $126.5 million as of FY2023, which was down 40.25% from $211.7 million recorded in FY2022.
  • Solid Biosciences' 5-year Common Equity high stood at $211.7 million for FY2022, and its period low was $80.0 million during FY2019.
  • In the last 3 years, Solid Biosciences' Common Equity had a median value of $208.2 million in 2021 and averaged $182.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first spiked by 65.01% in 2020, then tumbled by 40.25% in 2023.
  • Yearly analysis of 5 years shows Solid Biosciences' Common Equity stood at $80.0 million in 2019, then spiked by 65.01% to $132.1 million in 2020, then soared by 57.63% to $208.2 million in 2021, then climbed by 1.66% to $211.7 million in 2022, then tumbled by 40.25% to $126.5 million in 2023.